These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 8955908)

  • 1. Transcripts containing a small anti-HIV hammerhead ribozyme that are active in the cell cytoplasm but inactive in vitro as free RNAs.
    Domi A; Beaud G; Favre A
    Biochimie; 1996; 78(7):654-62. PubMed ID: 8955908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of structure in a long target RNA on ribozyme cleavage efficiency.
    Campbell TB; McDonald CK; Hagen M
    Nucleic Acids Res; 1997 Dec; 25(24):4985-93. PubMed ID: 9396806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme.
    Ojwang JO; Hampel A; Looney DJ; Wong-Staal F; Rappaport J
    Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10802-6. PubMed ID: 1438280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design.
    Tabler M; Homann M; Tzortzakaki S; Sczakiel G
    Nucleic Acids Res; 1994 Sep; 22(19):3958-65. PubMed ID: 7937118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A helix 1-extended hairpin ribozyme exhibits altered cleavage behavior in vitro.
    Moosbauer J; Tabler M
    Antisense Nucleic Acid Drug Dev; 1997 Apr; 7(2):79-87. PubMed ID: 9149843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.
    Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M
    Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.
    Bramlage B; Luzi E; Eckstein F
    Nucleic Acids Res; 2000 Nov; 28(21):4059-67. PubMed ID: 11058100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cleavage of full-length beta APP mRNA by hammerhead ribozymes.
    Denman RB
    Nucleic Acids Res; 1993 Aug; 21(17):4119-25. PubMed ID: 8371986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro cleavage of HIV-1 vif RNA by a synthetic ribozyme.
    Lorentzen EU; Wieland U; Kühn JE; Braun RW
    Virus Genes; 1991 Jan; 5(1):17-23. PubMed ID: 2017874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complex formation determines the activity of ribozymes directed against potato virus YN genomic RNA sequences.
    van der Vlugt RA; Prins M; Goldbach R
    Virus Res; 1993 Feb; 27(2):185-200. PubMed ID: 8460529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of HIV-specific ribozyme activity by self-cleavage.
    Ventura M; Wang P; Ragot T; Perricaudet M; Saragosti S
    Nucleic Acids Res; 1993 Jul; 21(14):3249-55. PubMed ID: 8341599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo.
    Ramezani A; Joshi S
    Antisense Nucleic Acid Drug Dev; 1996; 6(3):229-35. PubMed ID: 8915508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites.
    Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L
    Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates.
    Sioud M
    Nucleic Acids Res; 1997 Jan; 25(2):333-8. PubMed ID: 9016562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells.
    Yamada O; Kraus G; Leavitt MC; Yu M; Wong-Staal F
    Virology; 1994 Nov; 205(1):121-6. PubMed ID: 7975207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
    Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
    Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple folded conformations of a hammerhead ribozyme domain under cleavage conditions.
    Woisard A; Fourrey JL; Favre A
    J Mol Biol; 1994 Jun; 239(3):366-70. PubMed ID: 8201618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activities of HIV-RNA targeted ribozymes transcribed from a 'shot-gun' type ribozyme-trimming plasmid.
    Ohkawa J; Yuyama N; Taira K
    Nucleic Acids Symp Ser; 1992; (27):15-6. PubMed ID: 1289797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribozyme mediated destruction of influenza A virus in vitro and in vivo.
    Tang XB; Hobom G; Luo D
    J Med Virol; 1994 Apr; 42(4):385-95. PubMed ID: 8046429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.